Phytochemical-Based Drug Discovery for Breast Cancer: Combining Virtual Screening and Molecular Dynamics to Identify Novel Therapeutics.

Maternal Embryonic Leucine Zipper Kinase (MELK), a pivotal signaling protein, plays a crucial role in various physiological processes such as cell growth, survival, and differentiation. There is currently a growing interest in MELK as a promising therapeutic target for multiple cancers, including triple-negative breast cancer (TNBC). Exploring MELK as a target offers a prospective strategy to impede cancer progression and enhance the efficacy of conventional anticancer therapies.

Effect of labor analgesia using programmed intermittent epidural boluses on postpartum depression symptoms: A randomized controlled trial.

Background: Postpartum depression (PPD) is a serious concern with multifactorial etiology. Association between prenatal anxiety, pain, and depression has been theorized.

Aim: In this randomized controlled trial, we studied the effect of pain relief by combined spinal epidural (CSE) and other factors influencing PPD.

Outcomes after revision surgery for glenoid baseplate failure in reverse shoulder arthroplasty.

Background: The purpose of this study was to report clinical outcomes in patients who underwent revision surgery for glenoid baseplate failure after index reverse shoulder arthroplasty (RSA).

Methods: A retrospective review was performed to identify patients from 2010 to 2020 at a single institution who sustained glenoid baseplate failure after RSA and underwent revision surgery. Exclusion criteria included periprosthetic joint infection or lack of minimum 1 year clinical and radiographic follow-up.

Liposomal Formulation of Hydroxychloroquine Can Inhibit Autophagy In Vivo.

Preclinical studies have shown that the anti-malarial drug hydroxychloroquine (HCQ) improves the anti-cancer effects of various therapeutic agents by impairing autophagy. These findings are difficult to translate in vivo as reaching an effective HCQ concentration at the tumor site for extended times is challenging. Previously, we found that free HCQ in combination with gefitinib (Iressa, ZD1839) significantly reduced tumor volume in immunocompromised mice bearing gefitinib-resistant JIMT-1 breast cancer xenografts.